Medmix v. Kettenbach: Dental Mixing Cartridge Patents Settle After 1,137 Days
Medmix Switzerland AG, owner of the Mixpac cartridge and mixing tip platform, filed suit against German dental materials rival Kettenbach GmbH in the Eastern District of New York, asserting six patents covering impression materials and dispensing systems including Futar®, Identium®, Panasil®, and Silginat®. The parties reached a settlement in January 2025, closing the case after more than three years of litigation.
Six-patent dental materials fight ends in confidential settlement
On 26 November 2021, Medmix Switzerland AG — successor to Sulzer Mixpac and owner of the widely deployed Mixpac cartridge and mixing tip platform — filed an infringement action in the Eastern District of New York against Kettenbach GmbH & Co. KG, its U.S. subsidiary Kettenbach LP, and Xinial Systems GmbH & Co. KG. The complaint targeted six patents spanning dental impression materials and two-component dispensing technology, and named Kettenbach’s Futar®, Identium®, Panasil®, and Silginat® product lines as the accused products.
The case closed on 6 January 2025 after the parties filed a notice of settlement covering all claims and counterclaims. The court directed the Clerk to close the case subject to reopening within 60 days if the settlement was not consummated — a standard mechanism that suggests final execution was still pending at the time of the order. No judgment on the merits was entered, and settlement financial terms have not been disclosed on the public docket.
A duration of 1,137 days — approaching three and a half years — is consistent with complex multi-patent, multi-defendant litigation in the Eastern District of New York, where Markman hearings and parallel USPTO proceedings can extend timelines significantly. The confidential resolution leaves unanswered whether Kettenbach secured a licence, agreed to design-arounds, or whether any royalty stream was established; the public record does not permit further inference on those commercial terms.
Filing to Case Settled in 1137 days
1,137 days — approximately 37 months, well above the EDNY median for patent cases
Case settled: what the confidential resolution means for both parties
Settlement closes all claims and counterclaims without merits ruling
The court’s January 2025 order closed the case on receipt of the parties’ notice of settlement, with a 60-day window for reopening if the agreement was not finalised. A settlement at this stage terminates all infringement claims and any invalidity counterclaims Kettenbach may have asserted, without any judicial finding on liability or patent validity. The underlying patents remain presumptively valid.
No merits adjudicationMedmix avoids an invalidity ruling; commercial terms undisclosed
For Medmix, settlement preserves the enforceability of all six asserted patents — no court has found them invalid or not infringed. Whether Medmix secured a royalty, a lump-sum payment, or product design commitments from Kettenbach is not on the public record. The outcome is consistent with a plaintiff that saw sufficient risk in continued litigation to prefer a negotiated resolution over a verdict.
Patents remain enforceableKettenbach resolves exposure across three entities without infringement finding
Kettenbach GmbH, Kettenbach LP, and Xinial Systems each exit the litigation without an adverse infringement finding against them. Settlement extinguishes Medmix’s right to seek damages or an injunction under the asserted patents for the accused products, at least to the extent addressed in any licence or release. The absence of a public record on terms means competitors cannot determine whether Kettenbach’s product lines required modification.
No infringement findingDental impressions sector faces continued IP uncertainty around mixing systems
The settlement leaves Medmix’s patent portfolio intact and potentially available for further enforcement against other dental materials or dispensing system makers. Competitors developing two-component cartridge or mixing tip technologies should note that six patents survived three-plus years of litigation without invalidation. The outcome typically signals that the patent holder retains leverage for future licensing discussions in the dental dispensing space.
Portfolio enforcement risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Medmix Switzerland AG | Company | Dental dispensing systems maker — holder of Mixpac cartridge and mixing tip patentsSearch in Eureka ↗ |
| Defendant | Kettenbach GMBH and CO KG | Company | German dental materials manufacturer; markets Futar®, Identium®, Panasil®, and Silginat® impression productsSearch in Eureka ↗ |
| Co-Defendant | Kettenbach, LP | Company | Search in Eureka ↗ |
| Co-Defendant | Xinial Systems GmbH and Co., KG | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles D. Cole , Jr. | Attorney | Counsel for Medmix Switzerland AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel In Hwang | Attorney | Counsel for Medmix Switzerland AGSearch in Eureka ↗ |
| Plaintiff counsel | Joseph Arand | Attorney | Counsel for Medmix Switzerland AGSearch in Eureka ↗ |
| Plaintiff counsel | Lydia Anne Bayley | Attorney | Counsel for Medmix Switzerland AGSearch in Eureka ↗ |
| Plaintiff counsel | Michael T. Murphy | Attorney | Counsel for Medmix Switzerland AGSearch in Eureka ↗ |
| Plaintiff counsel | Suzanne Konrad | Attorney | Counsel for Medmix Switzerland AGSearch in Eureka ↗ |
| Plaintiff law firm | Global IP Counselors LLP | Law Firm | Representing Medmix Switzerland AGSearch in Eureka ↗ |
| Plaintiff law firm | Newman Myers Kreines Harris PC | Law Firm | Representing Medmix Switzerland AGSearch in Eureka ↗ |
| Defendant counsel | Alexander Edison Harding | Attorney | Counsel for Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant counsel | Annmarie Dressler | Attorney | Counsel for Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant counsel | Danny M. Awdeh | Attorney | Counsel for Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant counsel | David Mroz | Attorney | Counsel for Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant counsel | Jonathon Brugh Lower | Attorney | Counsel for Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant counsel | Matthew Ritter | Attorney | Counsel for Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant counsel | Robert King High , III | Attorney | Counsel for Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant counsel | Rosie Norwood-Kelly | Attorney | Counsel for Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant counsel | Wiliam Paul Deni , Jr. | Attorney | Counsel for Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant law firm | Cooley LLP | Law Firm | Representing Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant law firm | Finnegan Henderson Farabow Garrett & Dunner, LLP | Law Firm | Representing Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant law firm | Finnegan LLP | Law Firm | Representing Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant law firm | Gibbons PC | Law Firm | Representing Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Defendant law firm | White & Case LLP | Law Firm | Representing Kettenbach GMBH and CO KGSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New York Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order recites receipt of a ‘Notice of Settlement re all claims and counterclaims,’ directing case closure subject to a 60-day reopening window. This phrasing confirms the settlement is comprehensive — no claim or counterclaim survives — but the conditional reopening clause indicates formal execution was pending at the order date. Critically, no merits finding is embedded in the order: patent validity, infringement, and damages are all unresolved on the public record, leaving the six asserted patents undiminished in their presumptive enforceability.
US9010578B2 and five further patents — dental cartridge and mixing tip systems
The six asserted patents span multiple decades of dental dispensing innovation, ranging from foundational impression material chemistry to modern two-component cartridge architectures. US9010578B2, the most recent, covers the Mixpac-style cartridge and static mixing tip system that has become the de facto standard for delivering two-component dental impression and bite registration materials chairside. The portfolio collectively protects both the material formulations (covering products such as Futar®, Panasil®, and Silginat®) and the mechanical delivery platform, creating overlapping layers of IP protection.
For competitors in the dental materials and device sector, the breadth of this portfolio — spanning chemistry and hardware — is strategically significant. A company that designs around one layer of protection (e.g. reformulating an impression material) may still face exposure on the cartridge or mixing tip claims, and vice versa. The portfolio’s survival through 37 months of litigation without an invalidity ruling strengthens Medmix’s hand in any future licensing or enforcement action against other producers of two-component dental dispensing systems.
Should you run an FTO against US9010578B2 and the Mixpac patent portfolio?
Any R&D team or product manager developing two-component cartridge systems, static mixing tips, or dental impression materials for chairside delivery should treat this portfolio as a live enforcement risk. The case confirms Medmix is willing to litigate multi-party, multi-patent disputes to resolution, and the settlement preserves all six patents as fully enforceable. OEM suppliers, private-label manufacturers, and new market entrants in dental or analogous industrial mixing markets are all within the scope of potential exposure.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim scope of the Mixpac portfolio in minutes — identifying which claims require design-around work and which prior art references are most relevant to invalidity arguments. Run a claim-by-claim analysis across US9010578B2 and the five co-asserted patents to establish a defensible FTO position before commercial launch or before responding to a licence demand.
Run a freedom-to-operate analysis on US4051261A to assess your product’s exposure
Run FTO in Eureka →Similar dental materials and dispensing system patent cases
Explore patent infringement cases involving dental impression materials and two-component cartridge dispensing systems litigated in U.S. federal district courts.
What this case signals for the dental dispensing IP landscape
A six-patent, three-defendant action settling after 37 months carries clear signals for IP strategy in the dental materials sector.
Multi-patent stacking amplifies settlement pressure on defendants
Asserting six patents across impression materials and cartridge systems substantially raises the cost and complexity of defence. Competitors in the dental dispensing market should audit their product lines against Medmix’s portfolio before launch — the breadth of the patent set suggests any single design-around may be insufficient.
EDNY is an active venue for dental and med-tech patent enforcement
The Eastern District of New York handled this three-defendant, multi-patent dispute for over three years. IP teams monitoring Medmix’s enforcement posture should track filings in EDNY alongside the USPTO for any IPR or PGR proceedings that may have run in parallel.
Medmix v Kettenbach — key questions answered
Medmix asserted six patents: US4051261A, US4884886A, US4059599A, US5688539A, US9010578B2, and US2485852A. These collectively cover dental impression material formulations and two-component cartridge and static mixing tip dispensing systems. The accused products included Kettenbach’s Futar®, Identium®, Panasil®, and Silginat® lines.
The case settled in January 2025 after 1,137 days. The court closed the case on receipt of the parties’ notice of settlement covering all claims and counterclaims. No merits finding was entered, meaning all six asserted patents remain presumptively valid and enforceable. The financial terms of the settlement are confidential and not reflected in the public docket.
Three defendants were named: Kettenbach GmbH & Co. KG (the German parent), Kettenbach LP (the U.S. subsidiary), and Xinial Systems GmbH & Co. KG. Naming both the brand owner and a supply-chain entity like Xinial Systems is consistent with an enforcement strategy targeting the full distribution network, ensuring any injunctive relief or settlement obligations bind the entire commercial chain.
The Mixpac system, now owned by Medmix Switzerland AG, is a two-component dispensing platform widely used in dental practice to deliver impression and bite registration materials. It comprises a dual-barrel cartridge and a disposable static mixing tip that combines the two components upon dispensing. It is considered a de facto industry standard for chairside delivery of multi-component dental materials.
The case was filed on 26 November 2021 and closed on 6 January 2025 in the U.S. District Court for the Eastern District of New York (Case No. 2:21-cv-06613). The litigation ran for 1,137 days — approximately 37 months — before settling, which is consistent with the timeline of complex multi-patent, multi-defendant patent disputes in that district.
PatSnap Eureka searches patents and litigation data to answer instantly.